**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Prime Rounds CML | **Project Code** | PI4VGR101 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Nathan Kelly |
| **Compliance** | Briana Devaser | **Editor** | Trudy Stoddert |

**Launch Date/Internal Launch Date:**

**December 2014**

**Project Type**

Prime Rounds webinar recorded (video)

Downloadable Slides

Podcast

Other:

**Email Blast Included?**

Yes

No

**Subject Line:**

*Prime Rounds: The Evolving Landscape of CML Management*

**Number of E-Blasts**

Only One

Two  
Other Amount:

**Cross Promotion**

Yes

No

If Yes, List Activities: the Canadian CSP from ASH 2014

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)

Additional Emails (Supporters?): specific target list of canadian physicians only

Kostic, Ivana ([Ivana.Kostic@bms.com](mailto:Ivana.Kostic@bms.com))

Stavroula.Lestou@bms.com

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
Content Available by:

**CME?**

Yes

No

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**2014 PR CML**

Please add your content to the form below and remove any content that is irrelevant to your activity. If something gets updated, please update this document.

**\*\*\*DO NOT LIST “SEE ATTACHED DOCUMENT”.**

**This is the only copy document that should be sent to Design.\*\*\***

**Items highlighted in YELLOW should be completed by the Clinical Team**

**Items highlighted in TEAL should be determined at the Kickoff Meeting**

**In terms of LEAN, virtual products differ in that all sections should be complete prior to sending this form to Web (there is no minimum number of sections).**

1. **[Title]**

*prIME Rounds: The Evolving Landscape of CML Management*

1. **[Activity Date]**

**Release Date:**

December XX, 2014

**Expiration Date:**December XX, 2015

1. **[Activity Overview]**

This CME-certified prIME Rounds Webcast focuses on contemporary practices in the management of patients with chronic myeloid leukemia (CML).

1. **[Target Audience]**

This educational activity is specifically designed for specifically designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with CML.

1. **[Learning Objectives]**

After successful completion of this educational activity, participants should be able to:

* Evaluate therapeutic options for the individualized management of patients with CML, including considerations for therapy selection
* Evaluate the influence of adverse events and response monitoring with regard to treatment decision making practices for patients with CML
* Identify barriers to treatment success in patients with CML

1. **[Faculty Listing/Featured Experts/Discussants….Faculty Listing and Featured Experts sections are stacked, Discussants section is in-line]**

**Philipp le Coutre, MD**  
Charité-University Medicine Berlin  
Berlin, Germany

**Jeffrey Lipton, MD, PhD**  
Princess Margaret Cancer Centre  
University of Toronto  
Toronto, Ontario, Canada

1. **[Featured Abstracts/Discussion Topics/Activity Topics]**
2. **Provider**

This activity is provided by prIME Oncology.

1. **[Continuing Education]**

**US CME**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

[Insert ACCME logo]

prIME Oncology designates this enduring activity for a maximum of *1 AMA PRA Category 1 Credit™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*Please contact The Royal College Services Center at 1-800-461-9598 or at cpd@royalcollege.ca for instructions for reporting this activity in the MAINPORT*

**Method of Participation**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx) [[link to our Terms page]]

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with XX% or higher.

1. **Support Statement [ACCME—consult Cindy for proper verbiage and defer to BD for final approval of complete verbiage]**

This educational activity is supported by grant from Bristol-Myers Squibb.

1. **[Disclosures]**

**CME**

**Disclosure of Relevant Financial Relationships**

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr le Coutre has disclosed he received consultation fees from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. He also has performed contracted research for Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lipton has disclosed that he has received consulting fees from and has performed contracted research for Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Briana Betz, PhD (clinical content reviewer/planner) - no relevant financial relationships
* Trudy Stoddert, ELS (editorial content reviewer) - no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1. **[URL and Mobile App Name] \*\*\*Should be discussed and decided upon at the Kickoff Meeting.**

www.primeoncology.org/2014primerounds\_CML

Page Title

Primary Keyword | Secondary Keyword

Insert Mobile App Name (restricted to 23 characters, including spaces. Conference names and abbreviations [ie, ASCO, ISHL] are appropriate to use. Do not include the location or year in the title. For Web activities, it is not necessary to include the type of activity [ie, CSP, Expert Review] in the title, as this will be indicated below the title. For Webcasts, use the same app title as was used for the live activity): **2014 prIME Rounds CML**

Meta Description

Key Words/Key Phrases

1. **[Subject Line for Email Blast]**

New prIME Rounds: The Evolving Landscape of CML Management

1. **[Email Blast Copy]**

Either list parts above that are to be included in the email blast or insert new (different) copy that is to be used in the email blast.

Example:

Title

Date/Time

Faculty

Topics

Target Audience

Learning Objectives

Continuing Education Statement

Credit Designation Statement

Disclosures

Providership (with logos)

Support (with no logos)

Fee Statement